Dulaglutide

Generic Name: Dulaglutide

Brand Names: Trulicity

Drug Type: Biotech

Chemical Formula: -

CAS Number: 923950-08-7

Unique Ingredient Identifier: WTT295HSY5

Background: Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was appro...

Indication: Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular r...

Associated Conditions: Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake

Phase 2

Completed

Conditions: Thirst
Water-Electrolyte Imbalance

Interventions: Other: Placebo
Drug: Dulaglutide

First Posted Date: 2017-05-05

Last Posted Date: 2017-10-25

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 17

Registration Number: NCT03141632

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: tirzepatide
Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2017-04-27

Last Posted Date: 2019-08-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 318

Registration Number: NCT03131687

Locations: 🇸🇰
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Trenčín, Slovakia
🇸🇰
"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Trenčín, Slovakia
🇺🇸
National Research Institute, Los Angeles, California, United States

and more 38 locations

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Dulaglutide
Drug: Semaglutide

First Posted Date: 2017-01-09

Last Posted Date: 2021-03-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 458

Registration Number: NCT03015220

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Dulaglutide

First Posted Date: 2016-11-25

Last Posted Date: 2019-09-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 318

Registration Number: NCT02973100

Locations: 🇺🇸
Parexel Early Phase Unit at Glendale, Glendale, California, United States
🇺🇸
Marin Endocrine Associates, Greenbrae, California, United States
🇺🇸
Catalina Research Institute, LLC, Montclair, California, United States

and more 37 locations

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2016-11-15

Last Posted Date: 2022-07-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 154

Registration Number: NCT02963766

Locations: 🇺🇸
ECU Pediatric Specialty Care, Greenville, North Carolina, United States
🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸
Division of Endocrinology, Diabetes, and Metabolism, Los Angeles, California, United States

and more 58 locations

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: liraglutide
Drug: Insulin glargine/lixisenatide fixed ratio combination
Drug: exenatide
Drug: exenatide extended-release
Drug: albiglutide
Drug: dulaglutide

First Posted Date: 2016-06-01

Last Posted Date: 2022-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 514

Registration Number: NCT02787551

Locations: 🇺🇸
Investigational Site Number 8400033, Baltimore, Maryland, United States
🇺🇸
Investigational Site Number 8400079, Albany, New York, United States
🇺🇸
Investigational Site Number 8400019, Columbus, Ohio, United States

and more 121 locations

Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

Phase 2

Completed

Conditions: Primary Polydipsia

Interventions: Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2016-05-12

Last Posted Date: 2020-01-18

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 50

Registration Number: NCT02770885

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

Phase 1

Completed

Conditions: Healthy
Type 2 Diabetes Mellitus (T2DM)

Interventions: Drug: Placebo
Drug: Tirzepatide
Drug: Dulaglutide

First Posted Date: 2016-05-03

Last Posted Date: 2024-01-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 142

Registration Number: NCT02759107

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
🇺🇸
Miami Research Associates, South Miami, Florida, United States

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2016-04-25

Last Posted Date: 2019-09-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 159

Registration Number: NCT02750410

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tama, Japan
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokohama, Japan

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Dulaglutide
Drug: semaglutide

First Posted Date: 2016-01-06

Last Posted Date: 2019-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1201

Registration Number: NCT02648204

Locations: 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy